THE EFFECT OF FIRST-LINE BASED ON PLATIN AND TAXANE CHEMOTHERAPY ON DENDRITIC CELLS IN WOMEN SUFFERING FROM OVARIAN CANCER

被引：0
|
作者：
Kotarski, J. [1 ]
Wertel, I. W. I. [1 ]
Polak, G. P. G. [1 ]
机构：
[1] Med Univ Lublin, Chair & Dept Oncol Gynaecol & Gynaecol 1, Lublin, Poland
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2013年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with Metastatic Breast Cancer.
    Schwartzberg, L.
    Rubin, P.
    Patnaik, A.
    Itri, L.
    Olson, A. L.
    Seidman, A. D.
    CANCER RESEARCH, 2011, 71
  • [22] The effect of protocol inclusion on the outcomes of ovarian cancer patients receiving first-line chemotherapy.
    Brown, AK
    Donfrancesco, S
    Granai, CO
    Disilvestro, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 471S - 471S
  • [23] First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
    Marchetti, Claudia
    Muzii, Ludovico
    Romito, Alessia
    Panici, Pierluigi Benedetti
    ONCOTARGETS AND THERAPY, 2019, 12 : 1095 - 1103
  • [24] First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis
    Nerich, Virginie
    Chelly, Jennifer
    Montcuquet, Philippe
    Chaigneau, Loic
    Villanueva, Cristian
    Fiteni, Frederic
    Meneveau, Nathalie
    Perrin, Sophie
    Voidey, Aline
    Monnot, Tess
    Pivot, Xavier
    Limat, Samuel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (05) : 362 - 368
  • [25] First-line Bevacizumab plus Taxane-based Chemotherapy for Metastatic Breast Cancer: Cost-minimisation Analysis
    Nerich, Virginie
    Bazan, Fernando
    Compagnat, Fanny
    Dobi, Erion
    Villanueva, Cristian
    Chaigneau, Loic
    Perrin, Sophie
    Voidey, Aline
    Pivot, Xavier
    Limat, Samuel
    ANTICANCER RESEARCH, 2012, 32 (08) : 3547 - 3552
  • [26] First-line Bevacizumab Plus Taxane-based Chemotherapy for Metastatic Breast Cancer (mBC): Cost Minimisation Analysis
    Compagnat, F.
    Nerich, V.
    Bazan, F.
    Voidey, A.
    Villanueva, C.
    Dobi, E.
    Thiery-Vuillemin, A.
    Chaigneau, L.
    Pivot, X.
    Limat, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S260 - S260
  • [27] Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer
    Vasey, PA
    Paul, J
    Birt, A
    Junor, EJ
    Reed, NS
    Symonds, RP
    Atkinson, R
    Graham, J
    Crawford, SM
    Coleman, R
    Thomas, H
    Davis, J
    Eggleton, SPH
    Kaye, SB
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2069 - 2080
  • [28] CARBOPLATIN AND ETOPOSIDE AS FIRST-LINE CHEMOTHERAPY IN ADVANCED EPITHELIAL OVARIAN-CANCER
    EDELMANN, DZ
    PERETZ, T
    BARAK, V
    ANTEBY, SO
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1995, 5 (06) : 443 - 448
  • [29] Patients with carboplatin, paclitaxel, and epirubicin combination as first-line chemotherapy in ovarian cancer
    Kristensen, GB
    Havsten, H
    Kaern, J
    Tropé, C
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 96 - 96
  • [30] Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
    Conic, Irena
    Nedovic, Bojan
    Stojnev, Slavica
    Todorovska, Ilinka
    Dimitrijevic, Aleksandra
    Krstic, Miljan
    Djordjevic, Ivana
    Djordjevic, Biljana
    MEDICINA-LITHUANIA, 2022, 58 (05):
12345